Ankylosing spondylitis (AS) — now classified as axial spondyloarthritis (axSpA) — is a chronic inflammatory arthritis that primarily affects the spine and sacroiliac joints, causing progressive stiffness, pain, and in advanced cases, spinal fusion. It most commonly affects young men in their 20s–30s and is significantly underdiagnosed in South Africa. From a medical aid perspective, AS occupies a unique and frustrating position: it IS a PMB condition, but it is NOT on the CDL — meaning your chronic medication is not automatically funded as a minimum benefit in the way CDL conditions are.
What Is Ankylosing Spondylitis?
AS is a seronegative spondyloarthropathy — an inflammatory arthritis without rheumatoid factor. It is strongly associated with the HLA-B27 gene (present in 85–95% of AS patients, compared to 6–8% of the general SA population).
Core features: - Chronic inflammatory lower back pain (worse in the morning, improves with exercise, worse with rest — the opposite of mechanical back pain) - Sacroiliac joint inflammation — the hallmark - Progressive spinal inflammation (spondylitis), which in severe cases leads to syndesmophyte formation and spinal fusion ("bamboo spine") - Extra-articular features: anterior uveitis (eye inflammation — 30–40% of patients), psoriasis, inflammatory bowel disease (IBD)
Diagnosis: HLA-B27 testing, MRI of sacroiliac joints (the most sensitive early diagnostic tool), X-rays of spine and pelvis, clinical assessment (BASDAI score). Many SA patients wait 8–10 years for diagnosis — this is a global problem with AS.
IS Ankylosing Spondylitis a PMB Condition?
Yes — AS is a PMB Diagnosis and Treatment Pair. Your scheme must fund diagnosis and treatment of AS as a minimum benefit.
But here is the critical nuance that catches patients out:
AS is NOT on the CDL (the 27 Chronic Disease List conditions). The CDL is the list that funds chronic medication at no cost to the MSA for listed conditions. Because AS is not CDL, there is no automatic standalone CDL chronic medication benefit for AS treatment.
What this means in practice: - PMB covers acute hospital events related to AS (e.g., uveitis requiring emergency treatment, acute flare requiring hospitalisation, joint injection procedures) - Biologics and DMARDs for AS (adalimumab, etanercept, secukinumab, ixekizumab) are prescribed for chronic management — these must be motivated under the PMB pathway, not the CDL pathway
The PMB pathway for biologic therapy in AS: Your rheumatologist must submit a pre-authorisation request motivating that the biologic treatment is the minimum benefit for AS under the PMB regulations. This is a clinical-legal argument that schemes may contest — and where many AS patients face their biggest battles.
See the RA article for broader context on the biologic access landscape — the process is similar, though RA has CDL status which gives it a stronger legal footing.
How Does Medical Aid Cover AS?
| Service | PMB/CDL? | Typical cover | Notes |
|---|---|---|---|
| GP consultation | No | Day-to-day | |
| Rheumatologist consultation | No | Day-to-day | Shortfall likely; R1,500–R3,500/visit |
| HLA-B27 testing | No | Pathology benefit | R500–R800 |
| MRI sacroiliac joints (diagnostic) | No | Radiology benefit — pre-auth required | R4,000–R8,000 |
| CRP, ESR (inflammatory markers) | No | Pathology benefit | Inexpensive; follow-up |
| NSAIDs (naproxen, indomethacin, celecoxib) — first-line | No | Day-to-day | Cornerstone therapy; generic inexpensive |
| Methotrexate (peripheral joint involvement) | No | Day-to-day | Useful for peripheral arthritis; not effective for axial |
| Adalimumab (Humira) / etanercept (Enbrel) — TNF inhibitors | PMB pathway | Day-to-day — needs pre-auth | R8,000–R15,000/month; major cost driver |
| Secukinumab (Cosentyx) / ixekizumab — IL-17 inhibitors | PMB pathway | Day-to-day — needs pre-auth | IL-17 inhibitors preferred for AS with psoriasis/IBD-like features |
| Upadacitinib (JAK inhibitor) | PMB pathway | Day-to-day — needs pre-auth | Newer class; limited SA formulary access |
| Physiotherapy (core strengthening, posture) | No | Day-to-day — limited sessions | Essential for function; long-term programme needed |
| Anterior uveitis treatment (eye drops, corticosteroids) | No | Day-to-day | Flare management |
| Joint injection (hip, sacroiliac) | No | Day procedure benefit | Guided injection; R2,000–R5,000 |
The Biologic Access Challenge — The Key Advisory Point
TNF inhibitors (adalimumab, etanercept) are the evidence-based treatment for AS that has failed NSAIDs. The cost — R8,000–R15,000/month (R96,000–R180,000/year) — makes this one of the most expensive conditions to manage in SA private healthcare.
Without CDL status, biologics for AS must be accessed via the PMB pathway: 1. Your rheumatologist submits a pre-authorisation request for biologic therapy 2. The scheme's managed care organisation (MCO) reviews the clinical motivation 3. The MCO may apply a step-therapy protocol: NSAID failure documented → conventional DMARD trial → biologic 4. Approval is granted (ideally) or declined (common — the most contested area)
If your scheme declines biologic pre-authorisation: - Your rheumatologist should escalate with a stronger motivation referencing the PMB DTP - Appeal through the internal appeals process - Escalate to CMS if the PMB obligation is not being met
Biosimilar option: Biosimilar versions of adalimumab (e.g., Hadlima, Hyrimoz) are available in SA at R4,000–R8,000/month — significantly cheaper than the originator Humira. Ask your rheumatologist whether a biosimilar is clinically appropriate.
Day-to-Day Costs: What to Budget For
| Scenario | Estimated annual cost |
|---|---|
| NSAID-managed AS, well-controlled, rheumatologist 2×/year | R15,000 – R30,000 |
| Biologic (TNF inhibitor) — if scheme-funded under PMB | R96,000–R180,000 in biologic cost alone (scheme pays at tariff) |
| Biologic (biosimilar) — if partially funded | R48,000–R96,000 in drug costs + specialist fees |
| Physiotherapy (ongoing, partial scheme funding) | R15,000 – R40,000/year |
Key Questions to Ask Your Scheme
- Does my plan recognise AS as a PMB condition, and what is the pre-authorisation pathway for biologic therapy? Get the specific MCO process and contact number.
- Is there a step-therapy protocol I must complete before biologics are approved? Know what's required upfront.
- Is biosimilar adalimumab on my formulary? Biosimilars are equivalent and significantly cheaper.
- What is my specialist sub-limit for rheumatologist visits? 3–4 quarterly visits per year is typical.
- Does my plan have a managed care programme for inflammatory arthritis? Some schemes have dedicated inflammatory arthritis pathways.
Talk to Eldon
AS biologic access is one of the most contested medical aid areas in SA. AURA helps navigate the PMB pathway, compare plans with biologic formulary access, and identify the most cost-effective treatment options.
See which plans pay for ankylosing spondylitis →